Siteadmin, Bureaucrats, Check users, nsAm_Govt_101RO, nsAm_Govt_101RW, nsAm_Govt_101_ta, nsJudgesRO, nsJudgesRW, nsJudges_talkRO, nsJudges_talkRW, nsTeam2RO, nsTeam2RW, nsTeam2_talkRO, nsTeam2_talkRW, oversight, Administrators
125,794
edits
Changes
Jump to navigation
Jump to search
Line 6:
Line 6: − + + + + + +
Patients with serum zinc content at admission <50 µg/dl had a mortality of 21%, which was significantly higher than merely 5% mortality in patients having zinc at admission ≥50 µg/dl; p<0·001.
== Compilation ==
== Compilation ==
A compilation of coronavirus studies demonstrates the effectiveness of early treatment by hydroxychloroquine.<ref>https://c19study.com/</ref>
A compilation of more than 100 coronavirus studies demonstrates the effectiveness of early treatment by hydroxychloroquine.<ref>https://c19study.com/</ref>
== Zinc ==
Patients with serum zinc content at admission <50 µg/dl had a mortality of 21%, which was significantly higher than merely 5% mortality in patients having zinc at admission ≥50 µg/dl; p<0·001.
{{cquote|Serum zinc levels lower than 50 mcgg/dl at admission correlated with worse clinical presentation, longer time to reach stability and higher mortality.}}
<ref>https://www.medrxiv.org/content/10.1101/2020.10.07.20208645v1</ref>
== Effective as Preventive Treatment ==
== Effective as Preventive Treatment ==
{{cquote|Five randomized controlled clinical trials enrolling 5,577 patients were included. HCQ was associated with a 24% reduction in COVID-19 infection, hospitalization or death .... No serious adverse cardiac events were reported. The most common side effects were gastrointestinal.<br>Conclusion--Hydroxychloroquine use in outpatients reduces the incidence of the composite outcome of COVID-19 infection, hospitalization, and death. Serious adverse events were not reported and cardiac arrhythmia was rare.<ref>https://www.medrxiv.org/content/10.1101/2020.09.30.20204693v1</ref>}}
{{cquote|Five randomized controlled clinical trials enrolling 5,577 patients were included. HCQ was associated with a 24% reduction in COVID-19 infection, hospitalization or death .... No serious adverse cardiac events were reported. The most common side effects were gastrointestinal.<br>Conclusion--Hydroxychloroquine use in outpatients reduces the incidence of the composite outcome of COVID-19 infection, hospitalization, and death. Serious adverse events were not reported and cardiac arrhythmia was rare.<ref>https://www.medrxiv.org/content/10.1101/2020.09.30.20204693v1</ref>}}